Real-world study of the consumption between 2017 and 2020 of anti-cancer medications that inhibit cyclin- dependent kinases 4 and 6
Bull Cancer. 2023 Oct 4:S0007-4551(23)00366-1. doi: 10.1016/j.bulcan.2023.08.004. Online ahead of print.ABSTRACTThe real-world study of data from the Système National des Données de Santé (French System of Health Data) in relation to therapeutic indications that give entitlement to having Assurance Maladie (Health-Insurance Fund) pay for, or reimburse the cost of, inhibitors of cyclin-dependent kinases 4 and 6 (iCDK4/6) shows that the target population defined by the Haute Autorité de santé (HAS-National Health Authority) has been significantly exceeded ; in addition, there is a gap with respect to reimbursable indica...
Source: Bulletin du Cancer - October 6, 2023 Category: Cancer & Oncology Authors: Aude Expert Laurence Robba Gr égoire de Lagasnerie Paule Kujas Source Type: research
Risk of lung cancer among welders and flame cutters: A systematic review and meta-analysis of case controlled studies
CONCLUSION: As the association between lung cancer and occupational hazards from exposure to welding fumes is certain, there is a need to control and regulate industrial activities that involve welding and flame cutting. Already, restrictions on safe levels of fume in the workplace are in operation.PMID:37802714 | DOI:10.1016/j.bulcan.2023.08.003 (Source: Bulletin du Cancer)
Source: Bulletin du Cancer - October 6, 2023 Category: Cancer & Oncology Authors: Saptorshi Gupta Source Type: research
Real-world study of the consumption between 2017 and 2020 of anti-cancer medications that inhibit cyclin- dependent kinases 4 and 6
Bull Cancer. 2023 Oct 4:S0007-4551(23)00366-1. doi: 10.1016/j.bulcan.2023.08.004. Online ahead of print.ABSTRACTThe real-world study of data from the Système National des Données de Santé (French System of Health Data) in relation to therapeutic indications that give entitlement to having Assurance Maladie (Health-Insurance Fund) pay for, or reimburse the cost of, inhibitors of cyclin-dependent kinases 4 and 6 (iCDK4/6) shows that the target population defined by the Haute Autorité de santé (HAS-National Health Authority) has been significantly exceeded ; in addition, there is a gap with respect to reimbursable indica...
Source: Bulletin du Cancer - October 6, 2023 Category: Cancer & Oncology Authors: Aude Expert Laurence Robba Gr égoire de Lagasnerie Paule Kujas Source Type: research
Risk of lung cancer among welders and flame cutters: A systematic review and meta-analysis of case controlled studies
CONCLUSION: As the association between lung cancer and occupational hazards from exposure to welding fumes is certain, there is a need to control and regulate industrial activities that involve welding and flame cutting. Already, restrictions on safe levels of fume in the workplace are in operation.PMID:37802714 | DOI:10.1016/j.bulcan.2023.08.003 (Source: Bulletin du Cancer)
Source: Bulletin du Cancer - October 6, 2023 Category: Cancer & Oncology Authors: Saptorshi Gupta Source Type: research
Real-world study of the consumption between 2017 and 2020 of anti-cancer medications that inhibit cyclin- dependent kinases 4 and 6
Bull Cancer. 2023 Oct 4:S0007-4551(23)00366-1. doi: 10.1016/j.bulcan.2023.08.004. Online ahead of print.ABSTRACTThe real-world study of data from the Système National des Données de Santé (French System of Health Data) in relation to therapeutic indications that give entitlement to having Assurance Maladie (Health-Insurance Fund) pay for, or reimburse the cost of, inhibitors of cyclin-dependent kinases 4 and 6 (iCDK4/6) shows that the target population defined by the Haute Autorité de santé (HAS-National Health Authority) has been significantly exceeded ; in addition, there is a gap with respect to reimbursable indica...
Source: Bulletin du Cancer - October 6, 2023 Category: Cancer & Oncology Authors: Aude Expert Laurence Robba Gr égoire de Lagasnerie Paule Kujas Source Type: research
Risk of lung cancer among welders and flame cutters: A systematic review and meta-analysis of case controlled studies
CONCLUSION: As the association between lung cancer and occupational hazards from exposure to welding fumes is certain, there is a need to control and regulate industrial activities that involve welding and flame cutting. Already, restrictions on safe levels of fume in the workplace are in operation.PMID:37802714 | DOI:10.1016/j.bulcan.2023.08.003 (Source: Bulletin du Cancer)
Source: Bulletin du Cancer - October 6, 2023 Category: Cancer & Oncology Authors: Saptorshi Gupta Source Type: research
Ivosidenib-azacitidine in acute myeloid leukemia with IDH1R132 mutation
Bull Cancer. 2023 Oct 3:S0007-4551(23)00370-3. doi: 10.1016/j.bulcan.2023.08.008. Online ahead of print.NO ABSTRACTPMID:37798244 | DOI:10.1016/j.bulcan.2023.08.008 (Source: Bulletin du Cancer)
Source: Bulletin du Cancer - October 5, 2023 Category: Cancer & Oncology Authors: Yaquine Mechelfekh Lauris Gastaud Source Type: research
First line durvalumab and tremelimumab in combination with chemotherapy for non-oncogene addicted metastatic non-small cell lung cancer (NSCLC)
Bull Cancer. 2023 Sep 25:S0007-4551(23)00368-5. doi: 10.1016/j.bulcan.2023.08.006. Online ahead of print.NO ABSTRACTPMID:37758567 | DOI:10.1016/j.bulcan.2023.08.006 (Source: Bulletin du Cancer)
Source: Bulletin du Cancer - September 27, 2023 Category: Cancer & Oncology Authors: Marie Porte Thomas Pierret Source Type: research
First line durvalumab and tremelimumab in combination with chemotherapy for non-oncogene addicted metastatic non-small cell lung cancer (NSCLC)
Bull Cancer. 2023 Sep 25:S0007-4551(23)00368-5. doi: 10.1016/j.bulcan.2023.08.006. Online ahead of print.NO ABSTRACTPMID:37758567 | DOI:10.1016/j.bulcan.2023.08.006 (Source: Bulletin du Cancer)
Source: Bulletin du Cancer - September 27, 2023 Category: Cancer & Oncology Authors: Marie Porte Thomas Pierret Source Type: research
First line durvalumab and tremelimumab in combination with chemotherapy for non-oncogene addicted metastatic non-small cell lung cancer (NSCLC)
Bull Cancer. 2023 Sep 25:S0007-4551(23)00368-5. doi: 10.1016/j.bulcan.2023.08.006. Online ahead of print.NO ABSTRACTPMID:37758567 | DOI:10.1016/j.bulcan.2023.08.006 (Source: Bulletin du Cancer)
Source: Bulletin du Cancer - September 27, 2023 Category: Cancer & Oncology Authors: Marie Porte Thomas Pierret Source Type: research
First line durvalumab and tremelimumab in combination with chemotherapy for non-oncogene addicted metastatic non-small cell lung cancer (NSCLC)
Bull Cancer. 2023 Sep 25:S0007-4551(23)00368-5. doi: 10.1016/j.bulcan.2023.08.006. Online ahead of print.NO ABSTRACTPMID:37758567 | DOI:10.1016/j.bulcan.2023.08.006 (Source: Bulletin du Cancer)
Source: Bulletin du Cancer - September 27, 2023 Category: Cancer & Oncology Authors: Marie Porte Thomas Pierret Source Type: research
First line durvalumab and tremelimumab in combination with chemotherapy for non-oncogene addicted metastatic non-small cell lung cancer (NSCLC)
Bull Cancer. 2023 Sep 25:S0007-4551(23)00368-5. doi: 10.1016/j.bulcan.2023.08.006. Online ahead of print.NO ABSTRACTPMID:37758567 | DOI:10.1016/j.bulcan.2023.08.006 (Source: Bulletin du Cancer)
Source: Bulletin du Cancer - September 27, 2023 Category: Cancer & Oncology Authors: Marie Porte Thomas Pierret Source Type: research
First line durvalumab and tremelimumab in combination with chemotherapy for non-oncogene addicted metastatic non-small cell lung cancer (NSCLC)
Bull Cancer. 2023 Sep 25:S0007-4551(23)00368-5. doi: 10.1016/j.bulcan.2023.08.006. Online ahead of print.NO ABSTRACTPMID:37758567 | DOI:10.1016/j.bulcan.2023.08.006 (Source: Bulletin du Cancer)
Source: Bulletin du Cancer - September 27, 2023 Category: Cancer & Oncology Authors: Marie Porte Thomas Pierret Source Type: research
First line durvalumab and tremelimumab in combination with chemotherapy for non-oncogene addicted metastatic non-small cell lung cancer (NSCLC)
Bull Cancer. 2023 Sep 25:S0007-4551(23)00368-5. doi: 10.1016/j.bulcan.2023.08.006. Online ahead of print.NO ABSTRACTPMID:37758567 | DOI:10.1016/j.bulcan.2023.08.006 (Source: Bulletin du Cancer)
Source: Bulletin du Cancer - September 27, 2023 Category: Cancer & Oncology Authors: Marie Porte Thomas Pierret Source Type: research
Adjuvant olaparib - High risk early breast cancer with BRCA1 or BRCA2 germline mutation
Bull Cancer. 2023 Sep 14:S0007-4551(23)00340-5. doi: 10.1016/j.bulcan.2023.07.004. Online ahead of print.NO ABSTRACTPMID:37716861 | DOI:10.1016/j.bulcan.2023.07.004 (Source: Bulletin du Cancer)
Source: Bulletin du Cancer - September 16, 2023 Category: Cancer & Oncology Authors: Ma ëva Bonneau Audrey Bellesoeur Source Type: research
